1,25-Dihydroxyvitamin D Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line.

Vitamin D is a steroid hormone that confers anti-tumorigenic properties in prostate cells. Serum vitamin D deficiency has been associated with advanced prostate cancer (PCa), particularly affecting African American (AA) men. Therefore, elucidating the pleiotropic effects of vitamin D on signaling pathways, essential to maintaining non-malignancy, may provide additional drug targets to mitigate disparate outcomes for men with PCa, especially AA men. We conducted RNA sequencing on an AA non-malignant prostate cell line, RC-77N/E, comparing untreated cells to those treated with 10 nM of vitamin D metabolite, 1α,25(OH)D, at 24 h. Differential gene expression analysis revealed 1601 significant genes affected by 1α,25(OH)D treatment. Pathway enrichment analysis predicted 1α,25(OH)D mediated repression of prostate cancer, cell proliferation, actin cytoskeletal, and actin-related signaling pathways ( < 0.05). Prioritizing genes with vitamin D response elements and associating expression levels with overall survival (OS) in The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA PRAD) cohort, we identified (Anillin) and (Epithelial Cell Transforming 2) as potential prognostic PCa biomarkers. Both genes were strongly correlated and significantly downregulated by 1α,25(OH)D treatment, where low expression was statistically associated with better overall survival outcomes in the TCGA PRAD public cohort. Increased and mRNA gene expression was significantly associated with PCa, and Gleason scores using both the TCGA cohort ( < 0.05) and an AA non-malignant/tumor-matched cohort. Our findings suggest 1α,25(OH)D regulation of these biomarkers may be significant for PCa prevention. In addition, 1α,25(OH)D could be used as an adjuvant treatment targeting actin cytoskeleton signaling and actin cytoskeleton-related signaling pathways, particularly among AA men.